Catalog No.
DHB86906
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Humanized
Isotype
IgG1-nd
Clonality
Monoclonal
Applications
Research Grade Biosimilar
Target
HER1, Receptor tyrosine-protein kinase erbB-1, Proto-oncogene c-ErbB-1, Epidermal growth factor receptor, EGFR, ERBB1, ERBB
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P00533
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
EMD-72000, H425, h425, CAS: 339186-68-4
Clone ID
Matuzumab
Note
For research use only. Not suitable for clinical or therapeutic use.
The role of cetuximab and other epidermal growth factor receptor monoclonal antibodies in the treatment of advanced non-small cell lung cancer., PMID:18782080
The anti-EGFR monoclonal antibody blocks cisplatin-induced activation of EGFR signaling mediated by HB-EGF., PMID:19027738
[Targeting HER pathway in head and neck and thoracic cancers]., PMID:19433372
Different antiproliferative effects of matuzumab and cetuximab in A431 cells are associated with persistent activity of the MAPK pathway., PMID:19167213
A novel mechanism for anti-EGFR antibody action involves chemokine-mediated leukocyte infiltration., PMID:19208382
Phase I study of epirubicin, cisplatin and capecitabine plus matuzumab in previously untreated patients with advanced oesophagogastric cancer., PMID:19238629
Anti-epidermal growth factor receptor monoclonal antibodies in cancer treatment., PMID:19269105
Molecular determinants of response to matuzumab in combination with paclitaxel for patients with advanced non-small cell lung cancer., PMID:19276157
Extending outcomes: epidermal growth factor receptor-targeted monoclonal antibodies in non-small-cell lung cancer., PMID:19362943
Interaction between fatty acid synthase- and ErbB-systems in ovarian cancer cells., PMID:19467222
Cetuximab and other anti-epidermal growth factor receptor monoclonal antibodies in the treatment of non-small cell lung cancer., PMID:19482958
Refinement of the population pharmacokinetic model for the monoclonal antibody matuzumab: external model evaluation and simulations., PMID:19691369
[The current status of development of anti-EGFR antibodies]., PMID:20495305
Matuzumab plus epirubicin, cisplatin and capecitabine (ECX) compared with epirubicin, cisplatin and capecitabine alone as first-line treatment in patients with advanced oesophago-gastric cancer: a randomised, multicentre open-label phase II study., PMID:20497967
Peptide mimotopes recognized by antibodies cetuximab and matuzumab induce a functionally equivalent anti-EGFR immune response., PMID:20514015
Pemetrexed with or without matuzumab as second-line treatment for patients with stage IIIB/IV non-small cell lung cancer., PMID:20978446
Monoclonal antibodies against EGFR in non-small cell lung cancer., PMID:21109448
Anti-EGFR monoclonal antibody in cancer treatment: in vitro and in vivo evidence., PMID:21196277
Targeted signal-amplifying enzymes enhance MRI of EGFR expression in an orthotopic model of human glioma., PMID:21245103
A biparatopic anti-EGFR nanobody efficiently inhibits solid tumour growth., PMID:21520037
In-depth biophysical analysis of interactions between therapeutic antibodies and the extracellular domain of the epidermal growth factor receptor., PMID:22085444
Efficient blockade of Akt signaling is a determinant factor to overcome resistance to matuzumab., PMID:22185378
In situ analysis of mutant EGFRs prevalent in glioblastoma multiforme reveals aberrant dimerization, activation, and differential response to anti-EGFR targeted therapy., PMID:22232519
Anti-EGFR biparatopic-SEED antibody has enhanced combination-activity in a single molecule., PMID:22426455
Phase I study of matuzumab in combination with 5-fluorouracil, leucovorin and cisplatin (PLF) in patients with advanced gastric and esophagogastric adenocarcinomas., PMID:22763610
Metastatic gastric cancer - focus on targeted therapies., PMID:22807624
A phase I pharmacokinetic study of matuzumab in combination with paclitaxel in patients with EGFR-expressing advanced non-small cell lung cancer., PMID:22832803
EGFR-directed monoclonal antibodies in non-small cell lung cancer., PMID:23300028
[A perspective: role of targeted therapy in colon cancer]., PMID:23575231
Alpha-particle emitting 213Bi-anti-EGFR immunoconjugates eradicate tumor cells independent of oxygenation., PMID:23724085
Structural evaluation of EGFR inhibition mechanisms for nanobodies/VHH domains., PMID:23791944
²¹³Bi-anti-EGFR radioimmunoconjugates and X-ray irradiation trigger different cell death pathways in squamous cell carcinoma cells., PMID:24210808
A Complement-Optimized EGFR Antibody Improves Cytotoxic Functions of Polymorphonuclear Cells against Tumor Cells., PMID:26475927
[Research status quo and progression in targeted therapy for advanced gastric cancer]., PMID:27781258
Evaluation of short-term effectiveness of eight targeted agents combined with chemotherapy for treating esophageal-gastric junction adenocarcinoma: A network meta-analysis., PMID:28708307
Semi-synthetic vNAR libraries screened against therapeutic antibodies primarily deliver anti-idiotypic binders., PMID:28852148
Risk of fatigue in cancer patients receiving anti-EGFR monoclonal antibodies: results from a systematic review and meta-analysis of randomized controlled trial., PMID:29181651
Most clinical anti-EGFR antibodies do not neutralize both wtEGFR and EGFRvIII activation in glioma., PMID:31002307
The effects of somatic mutations on EGFR interaction with anti-EGFR monoclonal antibodies: Implication for acquired resistance., PMID:31228284
Improving antibody-based therapies by chemical engineering of antibodies with multimeric cell-penetrating peptides for elevated intracellular delivery., PMID:32184098
Ultrabright Terbium Nanoparticles for FRET Biosensing and in Situ Imaging of Epidermal Growth Factor Receptors*., PMID:32501573
Identification of a novel anti-EGFR nanobody by phage display and its distinct paratope and epitope via homology modeling and molecular docking., PMID:33130376
Diverse metabolic response of cancer cells treated with a 213Bi-anti-EGFR-immunoconjugate., PMID:33737524
Milking the Cow: Cattle-Derived Chimeric Ultralong CDR-H3 Antibodies and Their Engineered CDR-H3-Only Knobbody Counterparts Targeting Epidermal Growth Factor Receptor Elicit Potent NK Cell-Mediated Cytotoxicity., PMID:34759924
Simultaneous Imaging and Therapy Using Epitope-Specific Anti-Epidermal Growth Factor Receptor (EGFR) Antibody Conjugates., PMID:36145664
New Perspectives for Prosthetic Valve Endocarditis: Impact of Molecular Imaging by FISHseq Diagnostics., PMID:36318608
Pharmacophore-based virtual screening approaches to identify novel molecular candidates against EGFR through comprehensive computational approaches and in-vitro studies., PMID:36457709
Enhancing Neutrophil Cytotoxicity of a Panel of Clinical EGFR Antibodies by Fc Engineering to IgA3.0., PMID:38958494
Evaluation of a cIEF Fractionation Workflow for Offline MS Analysis of Charge Variants of the Monoclonal Antibody Matuzumab., PMID:39964944
An Anti-EGFR Antibody-Drug Radioconjugate Labeled with Actinium-225 Elicits Durable Antitumor Responses in KRAS- and BRAF-Mutant Colorectal Cancer., PMID:40126545
For research use only. Not for human or drug use.
